Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study
Background Coronavirus disease 2019 (COVID-19) is a new health problem discovered in 2019 thus requires biomarkers that can detect early tissue damage. Soluble receptor for advanced glycation end-products (sRAGE) is a biomarker that can be used to identify early lung damage. Objective Analyzing...
Saved in:
id |
id-langga.118465 |
---|---|
record_format |
dspace |
spelling |
id-langga.1184652023-04-03T06:52:10Z https://repository.unair.ac.id/118465/ Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study Saputra, Gusti NR. Meliana, Resti Yudhawati Fitriah, Munawaroh R Medicine (General) R5-920 Medicine (General) Background Coronavirus disease 2019 (COVID-19) is a new health problem discovered in 2019 thus requires biomarkers that can detect early tissue damage. Soluble receptor for advanced glycation end-products (sRAGE) is a biomarker that can be used to identify early lung damage. Objective Analyzing the association of serum sRAGE on COVID-19 severity. Methods This study employed a cross-sectional design with a consecutive sampling method. It was conducted from May 2020–October 2021. The number of participants in this study was 145 participants which were divided into 2 groups (non-severe = 47 and severe = 98). Association of sRAGE serum on COVID-19 severity was analyzed using the chi-square test, Fisher's exact test, independence t-test, Mann Withney test, and Spearman's rank test with p-value <0.05. Results The results of blood analysis showed several blood components such as leukocytes (9896.51 ± 4949.64/μL; z = 2.431; p = 0.015), lymphocytes (13.55 ± 8.48%; z = 2.256; p = 0.024), neutrophils (78.91 ± 10.50%; z = 2.464; p = 0.014), procalcitonin (0.92 ± 3.22 ng/mL; z = 3.323; p = 0.001), CRP (8.59 ± 7.62 mg/L; z = 2.114; p = 0.034), D-dimer (4360.29 ± 7797.81 ng/mL; z = 2.186; p = 0.029), and fibrinogen (474.58 ± 168.90 mg/dL; t = 0.383; p = 0.703). There was a significant comparison in serum sRAGE values in the non-severe group (0.78 [0.63–1.00] ng/mL) and severe group (1.47 [0.97–2.25] ng/mL; r = 7.154; p <0.001). There was a significant association between serum sRAGE and COVID-19 severity (r = 0.598; p <0.001). The cut-off value for serum sRAGE between the severe and non-severe groups was 0.985 ng/mL. This study obtained sensitivity of 73.5%, specificity of 74.5% OR 8.077 and AUC 0.868 95% CI. Conclusion There is a significant association between serum sRAGE and COVID-19 severity and there is also a significant difference in serum sRAGE in the two groups. Elsevier B.V 2022-02 Article PeerReviewed text en https://repository.unair.ac.id/118465/3/turnitin%204.pdf text en https://repository.unair.ac.id/118465/4/KELENGKAPAN.pdf text id https://repository.unair.ac.id/118465/11/Association%20of%20soluble%20receptor%20for%20advanced%20glycation%20end-products%20%28sRAGE%29%20serum%20on%20COVID-19%20severity%20A%20cross-sectional%20study.pdf text en https://repository.unair.ac.id/118465/14/Association%20of%20soluble%20receptor%20for%20advanced_compressed.pdf text id https://repository.unair.ac.id/118465/16/Karil%20Association%20of%20soluble%20receptor.pdf text en https://repository.unair.ac.id/118465/18/19%20artikel.pdf Saputra, Gusti NR. and Meliana, Resti Yudhawati and Fitriah, Munawaroh (2022) Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study. Annals of Medicine and Surgery, 74. ISSN 2049-0801 https://www.sciencedirect.com/science/article/pii/S2049080122000632 https://doi.org/10.1016/j.amsu.2022.103303 |
institution |
Universitas Airlangga |
building |
Universitas Airlangga Library |
continent |
Asia |
country |
Indonesia Indonesia |
content_provider |
Universitas Airlangga Library |
collection |
UNAIR Repository |
language |
English English Indonesian English Indonesian English |
topic |
R Medicine (General) R5-920 Medicine (General) |
spellingShingle |
R Medicine (General) R5-920 Medicine (General) Saputra, Gusti NR. Meliana, Resti Yudhawati Fitriah, Munawaroh Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study |
description |
Background
Coronavirus disease 2019 (COVID-19) is a new health problem discovered in 2019 thus requires biomarkers that can detect early tissue damage. Soluble receptor for advanced glycation end-products (sRAGE) is a biomarker that can be used to identify early lung damage.
Objective
Analyzing the association of serum sRAGE on COVID-19 severity.
Methods
This study employed a cross-sectional design with a consecutive sampling method. It was conducted from May 2020–October 2021. The number of participants in this study was 145 participants which were divided into 2 groups (non-severe = 47 and severe = 98). Association of sRAGE serum on COVID-19 severity was analyzed using the chi-square test, Fisher's exact test, independence t-test, Mann Withney test, and Spearman's rank test with p-value <0.05.
Results
The results of blood analysis showed several blood components such as leukocytes (9896.51 ± 4949.64/μL; z = 2.431; p = 0.015), lymphocytes (13.55 ± 8.48%; z = 2.256; p = 0.024), neutrophils (78.91 ± 10.50%; z = 2.464; p = 0.014), procalcitonin (0.92 ± 3.22 ng/mL; z = 3.323; p = 0.001), CRP (8.59 ± 7.62 mg/L; z = 2.114; p = 0.034), D-dimer (4360.29 ± 7797.81 ng/mL; z = 2.186; p = 0.029), and fibrinogen (474.58 ± 168.90 mg/dL; t = 0.383; p = 0.703). There was a significant comparison in serum sRAGE values in the non-severe group (0.78 [0.63–1.00] ng/mL) and severe group (1.47 [0.97–2.25] ng/mL; r = 7.154; p <0.001). There was a significant association between serum sRAGE and COVID-19 severity (r = 0.598; p <0.001). The cut-off value for serum sRAGE between the severe and non-severe groups was 0.985 ng/mL. This study obtained sensitivity of 73.5%, specificity of 74.5% OR 8.077 and AUC 0.868 95% CI.
Conclusion
There is a significant association between serum sRAGE and COVID-19 severity and there is also a significant difference in serum sRAGE in the two groups. |
format |
Article PeerReviewed |
author |
Saputra, Gusti NR. Meliana, Resti Yudhawati Fitriah, Munawaroh |
author_facet |
Saputra, Gusti NR. Meliana, Resti Yudhawati Fitriah, Munawaroh |
author_sort |
Saputra, Gusti NR. |
title |
Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study |
title_short |
Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study |
title_full |
Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study |
title_fullStr |
Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study |
title_full_unstemmed |
Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: A cross-sectional study |
title_sort |
association of soluble receptor for advanced glycation end-products (srage) serum on covid-19 severity: a cross-sectional study |
publisher |
Elsevier B.V |
publishDate |
2022 |
url |
https://repository.unair.ac.id/118465/3/turnitin%204.pdf https://repository.unair.ac.id/118465/4/KELENGKAPAN.pdf https://repository.unair.ac.id/118465/11/Association%20of%20soluble%20receptor%20for%20advanced%20glycation%20end-products%20%28sRAGE%29%20serum%20on%20COVID-19%20severity%20A%20cross-sectional%20study.pdf https://repository.unair.ac.id/118465/14/Association%20of%20soluble%20receptor%20for%20advanced_compressed.pdf https://repository.unair.ac.id/118465/16/Karil%20Association%20of%20soluble%20receptor.pdf https://repository.unair.ac.id/118465/18/19%20artikel.pdf https://repository.unair.ac.id/118465/ https://www.sciencedirect.com/science/article/pii/S2049080122000632 https://doi.org/10.1016/j.amsu.2022.103303 |
_version_ |
1762764014118502400 |